Congratulations to our talented team on their larger roles in developing cures for heart disease!

Congratulations to our diligent and talented team members who are taking on larger roles as we develop our novel technologies to cure atherosclerosis!

Dr. Daniel Clemens: Vice President of Biology
Dr. Keivan Sadrerafi: Director of Chemistry
Dr. Prerna Bhargava: Senior Scientist
Darren Dinh: Senior Research Associate/ Lab Manager

It is through the hard work of our dedicated team that we are able to take on the world’s leading killer!

About Cyclarity

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.cyclaritytx.com or send an email to press@cyclaritytx.com

Contact:

Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com

Cyclarity News:

Dr. Oki O’Connor talks with Phil Newman of Longevity.Technology about Cyclarity’s solution

Cyclarity Therapeutics February 3, 2023

Watch Cyclarity CEO of Scientific Affairs Dr. Oki O’Connor talk with Phil Newman of Longevity.Technology about Cyclarity’s elegant solution to one of the world’s biggest problems – atherosclerosis.

Congratulations to our talented team on their larger roles in developing cures for heart disease!

Cyclarity Therapeutics February 1, 2023

Congratulations to our diligent and talented team members who are taking on larger roles as we develop our novel technologies to cure atherosclerosis!

Longevity.Technology publishes report on atherosclerosis and Cyclarity’s novel approach

Cyclarity Therapeutics January 18, 2023

We invite you to read the Longevity.Technology report “Disease management to disease modification – removing plaque to undo atherosclerosis”.

Mike Kope talks with Phil Newman of Longevity.Technology about Cyclarity

Cyclarity Therapeutics November 16, 2022

Watch Cyclarity CEO of Corporate Affairs Mike Kope talk with Phil Newman of Longevity.Technology about tackling oxidized cholesterol and taking on the world’s biggest killer.

Mike Kope presents at the Rejuvenation Startup Summit 2022

Cyclarity Therapeutics November 15, 2022

Watch Cyclarity’s CEO of Corporate Affairs Mike Kope discuss company strategy and the work to prevent age-related conditions such as atherosclerosis, heart attack, and stroke by addressing the root cause at the Rejuvenation Startup Summit 2022.

Cyclarity Therapeutics has Moved to the Buck Institute for Research on Aging

Cyclarity Therapeutics June 24, 2022

Press Release Novato, CA, U.S., June 24, 2022 – Announcing our move to the Buck Institute for Research on Aging. Cyclarity Therapeutics (https://cyclaritytx.com) has just completed the move of its research and operations to the state-of-the-art

Underdog Pharmaceuticals has changed its name to Cyclarity Therapeutics

Cyclarity Therapeutics June 23, 2022

Press Release Novato, CA, U.S., June 24, 2022 – Announcing our corporate name change and new branding. We’re excited to announce that Underdog Pharmaceuticals has changed its name to Cyclarity Therapeutics. We remain exactly on

KIZOO Technology Capital owner Michael Greve discusses recent scientific advancements with Drug Discovery World

Cyclarity Therapeutics May 13, 2022

KIZOO Technology Capital owner Michael Greve discusses the recent scientific advancements in addressing the root causes of age-related diseases in the rejuvenation biotechnology sphere—including the work of Underdog Pharmaceuticals. As one of Kizoo’s key startups, Underdog’s goal is to deliver affordable therapeutics for the prevention of heart disease and stroke through the removal of arterial plaque.

Kizoo Portfolio Company Underdog Closes $10M Financing Round

Cyclarity Therapeutics September 23, 2021

Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo, has closed a $10 million round of capital. Kizoo led the company’s Series Seed II round, which saw participation from both existing and new investors.

Underdog was recently awarded the Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP). This will enable faster patient access to its groundbreaking treatment for the prevention of heart attacks and stroke. The company expects to begin clinical trials in 2023.

Underdog Pharmaceuticals Awarded ‘Innovation Passport’ by UK Regulators

Cyclarity Therapeutics September 8, 2021

Press Release Mountain View, CA, U.S., September 8, 2021 –Underdog Pharmaceuticals, Inc. (Underdog), a pre-clinical stage pharmaceutical company focusing on the treatment and reversal of age-related diseases, has been awarded an Innovation Passport under the

Underdog Pharmaceuticals Announces Successful Meeting with MHRA and Launch of Series A Campaign

Cyclarity Therapeutics June 4, 2021

Underdog Pharmaceuticals, Inc., a pharmaceutical company designing engineered cyclodextrins to address atherosclerosis and other serious diseases of aging, has concluded a successful meeting with the Medicines and Health products Regulatory Agency (MHRA) of the UK.

Underdog Pharmaceuticals Named A Lighthouse Investment by Kizoo Technology Ventures

Cyclarity Therapeutics May 28, 2021

Kizoo Technology Capital GmbH has recently announced a $362M commitment to invest in rejuvenation biotechnology. If you haven’t seen the compelling write-up in BioWorld Today, please take a moment to read it here. Underdog was

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
elementor	never	This cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_V7N7F63JHL	2 years	This cookie is installed by Google Analytics.
_gat_UA-205714048-1	1 minute	A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.

Cookie	Duration	Description
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.